Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial
暂无分享,去创建一个
M. Weichenthal | J. Utikal | D. Schadendorf | A. Gesierich | S. Ugurel | M. Heppt | R. Gutzmer | C. Loquai | M. Eckstein | M. Schlaak | U. Leiter | C. Pföhler | P. Mohr | F. Meier | Elias A. T. Koch | A. Petzold | A. Wessely | Harald Knorr | F. Rahimi | B. Schuler-Thurner | K. Thoms | N. Kreuzberg | Edgar Dippel | Elias A T Koch | Jessica C Hassel | Carola Berking | Markus Meissner | E. Dippel
[1] R. Duran,et al. Safety and Efficacy of Ipilimumab plus Nivolumab and Sequential Selective Internal Radiation Therapy in Hepatic and Extrahepatic Metastatic Uveal Melanoma , 2022, Cancers.
[2] M. Weichenthal,et al. Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity , 2022, Cancers.
[3] C. Gebhardt,et al. Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance? , 2021, Cancers.
[4] M. Weichenthal,et al. Clinical determinants of long-term survival in metastatic uveal melanoma , 2021, Cancer Immunology, Immunotherapy.
[5] M. Weichenthal,et al. Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis , 2021, Cancers.
[6] F. Wacker,et al. Chemosaturation with Percutaneous Hepatic Perfusion: Outcome and Safety in Patients with Metastasized Uveal Melanoma Chemosaturation durch perkutane hepatische Perfusion mit Melphalan bei hepatisch metastasiertem Aderhautmelanom: eine Überlebens- und Sicherheitsanalyse , 2021, RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren.
[7] J. Becker,et al. Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy , 2021, Nature communications.
[8] K. Lindblad,et al. Liver metastases inhibit immunotherapy efficacy , 2021, Nature medicine.
[9] R. Sullivan,et al. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study , 2020, Journal for immunotherapy of cancer.
[10] B. Loveday,et al. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. , 2019, HPB.
[11] J. Utikal,et al. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study , 2019, Journal of Immunotherapy for Cancer.
[12] I. Chervoneva,et al. A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis. , 2019, Radiology.
[13] P. Huppert,et al. Meta-Analysis in Metastatic Uveal Melanoma to Determine Progression-Free and Overall Survival Benchmarks: an International Rare Cancers Initiative (IRCI) Ocular Melanoma study. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] L. de Geus-Oei,et al. Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems’ Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial , 2019, CardioVascular and Interventional Radiology.
[15] M. Manns,et al. Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival , 2018, European Radiology.
[16] B. Stedman,et al. Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease , 2017, Journal of surgical oncology.
[17] Johannes Griss,et al. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance , 2017, Nature Communications.
[18] Arun D. Singh,et al. Uveal Melanoma: 5-Year Update on Incidence, Treatment, and Survival (SEER 1973-2013) , 2017, Ocular Oncology and Pathology.
[19] M. Manns,et al. Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors , 2017, Journal of Cancer Research and Clinical Oncology.
[20] D. Schadendorf,et al. Immunotherapy in melanoma: Recent advances and future directions. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[21] Arun D. Singh,et al. Laparoscopic management of liver metastases from uveal melanoma , 2016, Surgical Endoscopy.
[22] V. Servois,et al. Radiofrequency ablation and surgical resection of liver metastases from uveal melanoma. , 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[23] C. Nutting,et al. Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases , 2016, Annals of Surgical Oncology.
[24] S. Demaria,et al. Role of Local Radiation Therapy in Cancer Immunotherapy. , 2015, JAMA oncology.
[25] H. Ishwaran,et al. Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.
[26] T. Kivelä,et al. Very long-term prognosis of patients with malignant uveal melanoma. , 2003, Investigative ophthalmology & visual science.
[27] G. Long,et al. Site‐specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti–PD‐1 therapy , 2019, Cancer.
[28] R. Scully,et al. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. , 2001, Archives of ophthalmology.